Halozyme Therapeutics (NASDAQ:HALO) Issues FY 2024 Earnings Guidance
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) updated its FY 2024 earnings guidance on Thursday. The company provided EPS guidance of 3.650-4.050 for the period, compared to the consensus EPS estimate of 3.730. The company issued revenue guidance of $935.0 million-$1.0 billion, compared to the consensus revenue estimate of $947.3 million. Halozyme Therapeutics Trading Up […]
More Stories
Milton Strengthens to Hurricane as DeSantis Preps Gulf Coast for Category 3 Storm
By T. J. Muscaro TAMPA—Milton has intensified into a category 1 hurricane. According to the 2 p.m. ET advisory from...
Taiwan Says Ready for Communist Invasion, Report Warns of Economic Warfare
By Lily Zhou The people of Taiwan will defend the self-ruled island against a potential invasion by the communist party...
Lebanon: UNHCR chief issues urgent aid appeal to stem humanitarian catastrophe
The UN High Commissioner for Refugees called on Sunday for greater international support to stem the “humanitarian catastrophe” now engulfing...
Lebanon: UNHCR chief issues urgent aid appeal to stem humanitarian catastrophe
The UN High Commissioner for Refugees called on Sunday for greater international support to stem the “humanitarian catastrophe” now engulfing...
Musk Launches PAC to Back Candidates Focused on Secure Borders, Free Speech, Sensible Spending
By Tom Ozimek Business mogul Elon Musk has launched a new political action committee (PAC), called America PAC, to endorse...
Bank of South Carolina Co. (BKSC) To Go Ex-Dividend on October 8th
Bank of South Carolina Co. (NASDAQ:BKSC – Get Free Report) announced a quarterly dividend on Thursday, September 26th, NASDAQ reports....